Valuation: Fortress Biotech, Inc.

Market Cap 91.35M 79.15M 74.16M 67.64M 127M 8.71B 129M 872M 341M 4.36B 343M 336M 14.55B P/E 2026 *
1.15x
P/E 2027 * -5.5x
Enterprise Value 91.35M 79.15M 74.16M 67.64M 127M 8.71B 129M 872M 341M 4.36B 343M 336M 14.55B EV / Sales 2026 *
1.14x
EV / Sales 2027 * 0.74x
Free-Float
77.21%
Yield 2026 *
-
Yield 2027 * -
1 day+5.36%
1 week-1.43%
Current month-12.14%
1 month-16.67%
3 months+21.68%
6 months-21.20%
Current year-24.86%
1 week 2.57
Extreme 2.57
2.85
1 month 2.57
Extreme 2.57
3.84
Current year 2.18
Extreme 2.18
4.53
1 year 1.91
Extreme 1.911
4.53
3 years 1.24
Extreme 1.24
8.37
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
1/1/26 Free

Director

27,322 0.0880%
1/1/26 Free

Director

27,322 0.0880%
1/1/26 Free

Director

27,322 0.0880%
Change 5-day change 1-year change 3-year change Capi.($)
+5.36%-1.43%+36.82%-65.34% 91.35M
+0.12%+3.83%+43.38%-1.11% 79.68B
-3.73%+3.89%-1.33%+25.77% 50.61B
-0.72%-2.09%+15.76%+168.20% 48.81B
-0.66%+3.90%-48.98%-47.71% 46.91B
+2.44%+1.08%+62.00%-23.68% 30.86B
+5.12%+13.18%+148.13%-37.26% 25.42B
-0.25%+0.81%+47.98%+83.18% 24.48B
-0.42%+4.62%+0.16%+193.67% 21.2B
+0.17%+2.26%+70.79%+169.84% 16.39B
Average +0.09%+3.06%+37.47%+46.56% 34.44B
Weighted average by Cap. -0.63%+3.17%+28.69%+41.89%

Financials

2026 *2027 *
Net sales 79.88M 69.2M 64.84M 59.14M 111M 7.62B 113M 763M 298M 3.81B 300M 293M 12.72B 123M 107M 99.85M 91.07M 171M 11.73B 174M 1.17B 459M 5.87B 462M 452M 19.59B
Net income 90.51M 78.42M 73.47M 67.02M 126M 8.63B 128M 864M 338M 4.32B 340M 332M 14.41B -20.84M -18.05M -16.92M -15.43M -29.01M -1.99B -29.45M -199M -77.77M -995M -78.24M -76.54M -3.32B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
12/08/26 US$2.750 +5.36% 1,007,762
11/08/26 US$2.610 -5.09% 617,236
10/08/26 US$2.750 +3.00% 542,784
07/08/26 US$2.670 -3.61% 579,990
06/08/26 US$2.770 -0.72% 651,385
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.750USD
Average target price
11.00USD
Spread / Average Target
+300.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock